Latest news

Bioservo Technologies AB publishes prospectus (regulatory information)

Bulletin from Extraordinary General Meeting in Bioservo (regulatory information)

World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies


30 Aug, 2022  ·  Regulatory information

Bioservo Technologies AB brings forward the release of the interim report for the second quarter

The Board of Bioservo AB (publ) ("Bioservo" or the "Company") has today resolved to bring forward the release of the Company's interim report for the second quarter of 2022 to August 30, 2022 from August 31, 2022. The reason for this decision is that the work to finalize the report has progressed faster than expected and that the Company intends to carry out a preferential issue of shares in the size of SEK 30 million. The capitalization is planned to enable reinforcements of the commercial organization and the Company's production capacity ahead of the upcoming launch of Carbonhand 2.0 and to utilize the increasing interest in Ironhand 2.0 in the USA.

For further information please contact:
Petter Bäckgren, CEO
+46 8 21 17 10

Mikael Wester, Marketing Director
+46 8 21 17 10

The information in this press release is such that Bioservo Technologies AB (publ) is obliged to publish in accordance with EU Regulation on Market Abuse (MAR). The information was submitted for publication through the agency of above contact persons for publication on August 30, 2022 at 05:31 p.m. CEST.

About Bioservo Technologies
Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy, and efficient. The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength. Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB, +46(0)8-52800399, is the company’s Certified Adviser on Nasdaq First North

For more information, please visit